Cargando…

Specificity testing by point prevalence as a simple assessment strategy using the Roche Elecsys® anti-SARS-CoV-2 immunoassay

BACKGROUND: The detection of antibodies to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is mandatory for the diagnosis, retrospective assessment of disease progression, and correct evaluation of the current infection situation in the population. Many such assays have been launched by...

Descripción completa

Detalles Bibliográficos
Autores principales: Kittel, Maximilian, Findeisen, Peter, Muth, Maria-Christina, Thiaucourt, Margot, Gerhards, Catharina, Neumaier, Michael, Haselmann, Verena
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7872847/
https://www.ncbi.nlm.nih.gov/pubmed/33578017
http://dx.doi.org/10.1016/j.ijid.2021.02.024
_version_ 1783649267557072896
author Kittel, Maximilian
Findeisen, Peter
Muth, Maria-Christina
Thiaucourt, Margot
Gerhards, Catharina
Neumaier, Michael
Haselmann, Verena
author_facet Kittel, Maximilian
Findeisen, Peter
Muth, Maria-Christina
Thiaucourt, Margot
Gerhards, Catharina
Neumaier, Michael
Haselmann, Verena
author_sort Kittel, Maximilian
collection PubMed
description BACKGROUND: The detection of antibodies to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is mandatory for the diagnosis, retrospective assessment of disease progression, and correct evaluation of the current infection situation in the population. Many such assays have been launched by various manufacturers. Unfortunately, the new US Food and Drug Administration emergency use regulations have resulted in a situation where laboratories have to perform their own validation studies but many of these laboratories do not have the biobank needed to conduct the studies. METHODS: We introduce a method that allows institutions to quickly perform a verification study in a low-prevalence infection situation. As proof of concept, we used the Roche Elecsys® anti-SARS-CoV-2 electrochemiluminescence immunoassay and an SAP-based hospital information system. The Shenzhen YHLO Biotech IgM and IgG assay targeting other surface patterns was used as a confirmatory test. RESULTS: The Roche assay demonstrated a limit of detection of 0.069 cutoff index and successfully passed the performance validation according to Clinical and Laboratory Standards Institute EP15-A3. The study population of 627 inpatients has a median age of 64 years, and approximately 13% of the group were under intensive care at the respective time point. All patients included tested negative for SARS-CoV-2 infection by quantitative reverse transcription polymerase chain reaction (cobas® 6800, Roche, Mannheim, Germany). Only one false-positive result was obtained, resulting in a specificity for the Roche Elecsys anti-SARS-CoV-2 test of 99.84% and a negative predictive value of 99.98%. CONCLUSIONS: The anonymized use of residual material enables quick evaluation of anti-SARS-CoV-2 immunoassays, as shown in this work with the Roche Elecsys assay. Comparison of the control population with economic data makes it possible to validate the sampling set and therefore to determine diagnostic specificity. By use of the approach chosen, it was shown that the Roche test achieved very good results in terms of diagnostic specificity, reproducibility, and limit of detection.
format Online
Article
Text
id pubmed-7872847
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
record_format MEDLINE/PubMed
spelling pubmed-78728472021-02-10 Specificity testing by point prevalence as a simple assessment strategy using the Roche Elecsys® anti-SARS-CoV-2 immunoassay Kittel, Maximilian Findeisen, Peter Muth, Maria-Christina Thiaucourt, Margot Gerhards, Catharina Neumaier, Michael Haselmann, Verena Int J Infect Dis Article BACKGROUND: The detection of antibodies to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is mandatory for the diagnosis, retrospective assessment of disease progression, and correct evaluation of the current infection situation in the population. Many such assays have been launched by various manufacturers. Unfortunately, the new US Food and Drug Administration emergency use regulations have resulted in a situation where laboratories have to perform their own validation studies but many of these laboratories do not have the biobank needed to conduct the studies. METHODS: We introduce a method that allows institutions to quickly perform a verification study in a low-prevalence infection situation. As proof of concept, we used the Roche Elecsys® anti-SARS-CoV-2 electrochemiluminescence immunoassay and an SAP-based hospital information system. The Shenzhen YHLO Biotech IgM and IgG assay targeting other surface patterns was used as a confirmatory test. RESULTS: The Roche assay demonstrated a limit of detection of 0.069 cutoff index and successfully passed the performance validation according to Clinical and Laboratory Standards Institute EP15-A3. The study population of 627 inpatients has a median age of 64 years, and approximately 13% of the group were under intensive care at the respective time point. All patients included tested negative for SARS-CoV-2 infection by quantitative reverse transcription polymerase chain reaction (cobas® 6800, Roche, Mannheim, Germany). Only one false-positive result was obtained, resulting in a specificity for the Roche Elecsys anti-SARS-CoV-2 test of 99.84% and a negative predictive value of 99.98%. CONCLUSIONS: The anonymized use of residual material enables quick evaluation of anti-SARS-CoV-2 immunoassays, as shown in this work with the Roche Elecsys assay. Comparison of the control population with economic data makes it possible to validate the sampling set and therefore to determine diagnostic specificity. By use of the approach chosen, it was shown that the Roche test achieved very good results in terms of diagnostic specificity, reproducibility, and limit of detection. The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases. 2021-04 2021-02-10 /pmc/articles/PMC7872847/ /pubmed/33578017 http://dx.doi.org/10.1016/j.ijid.2021.02.024 Text en © 2021 The Authors Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Article
Kittel, Maximilian
Findeisen, Peter
Muth, Maria-Christina
Thiaucourt, Margot
Gerhards, Catharina
Neumaier, Michael
Haselmann, Verena
Specificity testing by point prevalence as a simple assessment strategy using the Roche Elecsys® anti-SARS-CoV-2 immunoassay
title Specificity testing by point prevalence as a simple assessment strategy using the Roche Elecsys® anti-SARS-CoV-2 immunoassay
title_full Specificity testing by point prevalence as a simple assessment strategy using the Roche Elecsys® anti-SARS-CoV-2 immunoassay
title_fullStr Specificity testing by point prevalence as a simple assessment strategy using the Roche Elecsys® anti-SARS-CoV-2 immunoassay
title_full_unstemmed Specificity testing by point prevalence as a simple assessment strategy using the Roche Elecsys® anti-SARS-CoV-2 immunoassay
title_short Specificity testing by point prevalence as a simple assessment strategy using the Roche Elecsys® anti-SARS-CoV-2 immunoassay
title_sort specificity testing by point prevalence as a simple assessment strategy using the roche elecsys® anti-sars-cov-2 immunoassay
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7872847/
https://www.ncbi.nlm.nih.gov/pubmed/33578017
http://dx.doi.org/10.1016/j.ijid.2021.02.024
work_keys_str_mv AT kittelmaximilian specificitytestingbypointprevalenceasasimpleassessmentstrategyusingtherocheelecsysantisarscov2immunoassay
AT findeisenpeter specificitytestingbypointprevalenceasasimpleassessmentstrategyusingtherocheelecsysantisarscov2immunoassay
AT muthmariachristina specificitytestingbypointprevalenceasasimpleassessmentstrategyusingtherocheelecsysantisarscov2immunoassay
AT thiaucourtmargot specificitytestingbypointprevalenceasasimpleassessmentstrategyusingtherocheelecsysantisarscov2immunoassay
AT gerhardscatharina specificitytestingbypointprevalenceasasimpleassessmentstrategyusingtherocheelecsysantisarscov2immunoassay
AT neumaiermichael specificitytestingbypointprevalenceasasimpleassessmentstrategyusingtherocheelecsysantisarscov2immunoassay
AT haselmannverena specificitytestingbypointprevalenceasasimpleassessmentstrategyusingtherocheelecsysantisarscov2immunoassay